Atypical breast adenosquamous carcinoma following acute myeloid leukemia in a middle-aged woman: A case report
Autor: | Shokoufeh Mahmoudi Shan, Mahdi Jahantigh, Seyed Mehdi Hashemi, Abolghasem Allahyari |
---|---|
Rok vydání: | 2017 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty business.industry Adenosquamous carcinoma medicine.medical_treatment Metaplastic carcinoma Cancer Myeloid leukemia Articles medicine.disease Targeted therapy Radiation therapy 03 medical and health sciences 0302 clinical medicine Breast cancer Trastuzumab 030220 oncology & carcinogenesis Internal medicine Medicine 030212 general & internal medicine skin and connective tissue diseases business medicine.drug |
Zdroj: | Molecular and Clinical Oncology. 6:271-275 |
ISSN: | 2049-9469 2049-9450 |
DOI: | 10.3892/mco.2017.1124 |
Popis: | Adenosquamous carcinoma of the breast is a rare cancer that develops as glands and tubules admixed with solid nests of squamous cells in a spindle cell background. Furthermore, its occurrence following AML is also rare. To the best of our knowledge, based on a review of the relevant literature, thus far there have not been any welldocumented cases. In the present case report, we report on a middle-aged woman with a 2year history of acute myeloid leukemia (AML) who was admitted to hospital due to a mass in the right breast, with concurrent cutaneous lesions on the breast. The clinical and pathological investigations resulted in the diagnosis of adenosquamous carcinoma of the breast. The patient underwent a modified radical mastectomy (MRM). Subsequently, the patient received chemotherapy, involved-field radiation therapy and target therapy. At 9 months after the final cycle of chemotherapy, and while she was on targeted therapy with trastuzumab (6 mg administered every 3 weeks), the patient presented with extensive dermatomal skin lesions. A biopsy report revealed metastatic lesions of invasive ductal carcinoma in the abdomen, so chemotherapy resumed with a course lasting for 6 cycles, with the identical treatments, but lacking trastuzumab. |
Databáze: | OpenAIRE |
Externí odkaz: |